No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet
been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with
SAD will evaluate the efficacy, tolerability and safety of CBD oil (CHI-902) in SAD. In
addition, the effects of treatment with CHI-902 on the Endocannabinoid System (ECS) will be
assessed by evaluating peripheral endocannabinoids (Arachidonoylethanolamide/Anandamide (AEA)
and 2-Arachidonoyl glycerol (2-AG)) before and after treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Canopy Growth Corporation Canopy Health Innovations
Collaborators:
Centre for Addiction and Mental Health McMaster University